

**PRESS RELEASE**

Solna, 11 June 2021

**Interviews with CEO Hans Arwidsson**

**Eurocine Vaccines AB has published two interviews with CEO Hans Arwidsson in connection with the ongoing preferential issue of units. The interviews, which have partly different content, are in writing and in English and Swedish, respectively.**

For interview in English, please see:

[Interview with CEO Hans Arwidsson at IPOhub](#)

For interview in Swedish, please see:

[Interview with CEO Hans Arwidsson at Stockpicker](#)

**Contact**

If you have any questions, please contact CEO Hans Arwidsson

E-mail: [hans.arwidsson@eurocine-vaccines.com](mailto:hans.arwidsson@eurocine-vaccines.com)

Phone: +46 70 634 0171

**About Eurocine Vaccines**

Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.

Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.

The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.

Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.